18436-71-0

Basic information

• Product Name: 4-Chloro-6-methylquinoline
• Synonyms: 4-CHLORO-6-METHYLQUINOLINE
• CAS NO: 18436-71-0
• Molecular Formula: C₁₀H₈ClN
• Molecular Weight: 177.63
• EINECS: -0
• Mol File: 18436-71-0.mol
• Article Data: 6

Chemical Properties

• Melting Point: 51.0 to 55.0 °C
• Boiling Point: 140°C/10mmHg(lit.)
• Flash Point: 146.9 °C
• Appearance: /
• Density: 1.225g/cm³
• Vapor Pressure: 0.00848mmHg at 25°C
• Refractive Index: 1.634
• Storage Temp.: 2-8°C
• PKA: 3.79±0.16(Predicted)
• CAS DataBase Reference: 4-Chloro-6-methylquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chloro-6-methylquinoline(18436-71-0)
• EPA Substance Registry System: 4-Chloro-6-methylquinoline(18436-71-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22-37/38-41
• Safety Statements: 26-39
• WGK Germany: 3
• Hazardous Substances Data: 18436-71-0(Hazardous Substances Data)

Usage

General Description

4-Chloro-6-methylquinoline is a chemical compound consisting of a quinoline ring with a chlorine atom at the 4th position and a methyl group at the 6th position. It is primarily used in the pharmaceutical industry as an intermediate for the synthesis of various drugs and pharmaceutical compounds. 4-Chloro-6-methylquinoline has applications in the production of antimalarial drugs, as well as in the development of potential anticancer and antiviral agents. It is also used as a building block in the synthesis of various heterocyclic compounds and organic molecules. 4-Chloro-6-methylquinoline is considered to be a valuable chemical for medicinal and pharmaceutical research due to its potential biological activities and therapeutic applications.

InChI:InChI=1/C10H8ClN/c1-7-2-3-10-8(6-7)9(11)4-5-12-10/h2-6H,1H3

Upstream product

• 23432-40-8 4-hydroxy-6-methylquinoline 
• 91-62-3 6-methylquinoline 
• 25063-44-9 2,2-Dimethyl-5-(p-tolylamino-methylene)-[1,3]dioxane-4,6-dione 
• 23432-40-8 6-methyl-4(1H)-quinolinone 
• 106-49-0 p-toluidine 
• 19056-84-9 diethyl 2-[(p-tolylamino)methylidene]malonate 
• 79607-24-2 6-methyl-4-carbonylquinoline-3-carboxylic acid ethyl ester 

Downstream Products

• 123636-88-4 (S)-2-{4-[(4-Chloro-quinolin-6-ylmethyl)-ethyl-amino]-benzoylamino}-pentanedioic acid 
• 611-35-8 4-chloroquinoline 
• 1621082-95-8 4-methyl-N-(4-methyl-2-{1-[(4-methylphenyl)sulfonyl]-1Hpyrazol-3-yl}phenyl)benzenesulfonamide 
• 1082748-37-5 C₁₀H₁₁N₃ 
• 826-77-7 4,6-dimethylquinoline 

Relevant articles and documents

Development of novel quinoline-based sulfonamides as selective cancer-associated carbonic anhydrase isoform ix inhibitors

A new series of quinoline-based benzenesulfonamides (QBS) were developed as potential carbonic anhydrase inhibitors (CAIs). The target QBS CAIs is based on the 4-anilinoquinoline scaffold where the primary sulphonamide functionality was grafted at C4 of t

Further studies on bis-charged tetraazacyclophanes as potent inhibitors of small conductance Ca2+-activated K+ channels

Previously, quinolinium-based tetraazacyclophanes, such as UCL 1684 and UCL 1848, have been shown to be extraordinarily sensitive to changes in chemical structure (especially to the size of the cyclophane system) with respect to activity as potent non-peptidic blockers of the small conductance Ca 2+-activated K+ ion channels (SKCa). The present work has sought to optimize the structure of the linking chains in UCL 1848. We report the synthesis and SKCa channel-blocking activity of 29 analogues of UCL 1848 in which the central CH2 of UCL 1848 is replaced by other groups X or Y = O, S, CF2, CO, CHOH, CC, CHCH, CHMe to explore whether subtle changes in bond length or flexibility can improve potency still further. The possibility of improving potency by introducing ring substituents has also been explored by synthesizing and testing 25 analogues of UCL 1684 and UCL 1848 with substituents (NO2, NH2, CF 3, F, Cl, CH3, OCH3, OCF3, OH) in the 5, 6 or 7 positions of the aminoquinolinium rings. As in our earlier work, each compound was assayed for inhibition of the afterhyperpolarization (AHP) in rat sympathetic neurons, an action mediated by the SK3 subtype of the SK Ca channel. One of the new compounds (39, R7 = Cl, UCL 2053) is twice as potent as UCL 1848 and UCL 1684: seven are comparable in activity.

Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds

The compounds of formula I herein exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, for treating a patient suffering from, or subject to, a physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.